Bausch Health Companies (BHC) PT Lowered to $35 at Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mail
Get Alerts BHC Hot Sheet
Rating Summary:
11 Buy, 15 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 9 | New: 6
Join SI Premium – FREE
Cowen analyst Ken Cacciatore lowered the price target on Bausch Health Companies (NYSE: BHC) to $35.00 (from $40.00) while maintaining a Outperform rating following results.
The analyst commented, "Q3 revs reached $2.05B, in line, driven by recovery in all major segments including Salix, Solta, and International. Nonethless, the focus remains on Xifaxan's durability and we continue to believe the largest hurdle for a potential generic exclusivity trigger will be if Norwich can meet the stringent product-specific ANDA guidance for approval issued by the FDA, which could take years."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Upgrades Sandfire Resources NL (SFR:AU) (SNDFY) to Buy
- WAVE Life Sciences (WVE) PT Lowered to $29 at Oppenheimer
- SoFi Technologies (SOFI) PT Raised to $16.50 at BofA Securities
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT ChangeRelated Entities
Cowen & Co, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
